



## Cumulative Index 2003

### Volume 30

March	ETHICS IN PERINATAL MEDICINE, pages 1–187
June	EVIDENCE-BASED MEDICINE, pages 189–438
September	MATERNAL-FETAL SURGERY, pages 439–649
December	PRETERM LABOR, pages 651–894

*Note:* Page numbers of article titles are in **boldface** type.

### A

Abacavir, for HIV infection, in pregnancy, labor and delivery, 862

#### Abortion

##### induced

- fetal personhood and, 158
- for anomalies, 113–114
- availability of, 117
- decision-making on, 113–114, 118–119
- legality of, 71
- methods for, 119
- viability definition and, 119–121
- for genetic indications, 90–91
- for nonmedical reasons, FIGO ethical guidelines for, 57–59
- for sex selection, 89
- selective. *See* Selective termination.
- terminology recommendations for, 20

Academic performance, follow-up data in, 231–232

Acardiac twin, in twin reversed arterial perfusion sequence, 602–603

Access to care, in managed care, 172–173

AIDS. *See* Human immunodeficiency virus infection.

American College of Surgeons, guidelines of, for maternal-fetal surgery, 142

American Society for Reproductive Medicine Ethics Committee, on gender selection, 75–76

Aminophylline, for preterm labor, 821

#### Amniocentesis

- for anomaly detection
- emotional support for, 115
- failure to inform about, 114
- premature membrane rupture in, amniopatch technique for, 574–580
- serial, for twin-twin transfusion syndrome, 594–597

Amnionitis. *See* Chorioamnionitis.

#### Amniotic fluid

- abnormal volumes of. *See* Oligohydramnios; Polyhydramnios.
- amniopatch technique involving, for premature membrane rupture, 574–580, 586–587
- culture of, 683–684
- in gastroschisis, 559–564
- exchange or infusion of, 561–564
- inflammatory effects of, 559–561

Amoxicillin, for intrauterine infections, 688–689, 691

Ampicillin, for intrauterine infections, 687, 689

Amprenavir, for HIV infection, in pregnancy, labor and delivery, 863

Anastomoses, placental, in twin-twin transfusion syndrome, 592–593

Anencephaly, viability questions in, 119–121

Aneuploidy, nuchal translucency screening for, 95–102

- reliability of, 95–98
- respect for autonomy in, 100
- risks versus benefits of, 98–99

- Anhydramnios  
  in fetal distal urinary obstruction, 507,  
    511-512, 515  
  in gastroschisis, 553
- Anomalies, fetal. *See* Fetus, anomalies in.
- Antenatal surgery. *See* Maternal-fetal surgery.
- Antibiotics  
  for asymptomatic premature infants,  
    treatment decisions in. *See*  
    Treatment decisions.  
  for intrauterine infections, 687-691,  
    718-720  
  for preterm premature rupture of  
    membranes, 828-829
- Aortic stenosis, treatment of, 544-545
- Apnea, neonatal, methylxanthines for,  
  treatment decisions in. *See*  
  Treatment decisions.
- Arachidonic acid, in prostaglandin synthesis, in  
  uterine activity, 807
- Ascites, in distal urinary tract obstruction, 510
- Assisted reproduction technologies  
  multifetal pregnancy in. *See*  
    Multifetal pregnancy.  
  preterm birth risk with, 659
- Atazanvir, for HIV infection, in pregnancy,  
  labor and delivery, 863
- Atosiban, for preterm labor, 822, 849
- Atrial septum, intact, treatment of, 545-546
- Autonomy  
  in decision-making about fetal anomalies,  
    118-119  
  in maternal-fetal surgery for spina  
    bifida, 453-455  
  reproductive freedom component of, 114  
  respect for, in nuchal translucency  
    screening, 100
- B**
- Bacterial vaginosis, preterm birth in, 655-656,  
  686-687, 690-691
- Balloon  
  for tracheal occlusion, in congenital  
    diaphragmatic hernia, 469-473  
  for valvuloplasty. *See*  
    Valvuloplasty, balloon.
- Bayley Scales of Infant Development,  
  follow-up data in, 228
- Bedrest, for preterm labor, 813-814
- Benchmarking techniques, 343-350  
  abuses of, 347  
  limitations of, 345  
  patient protection in, 348  
  to improve quality of practice, 348-349  
  uses of, 344-346
- Beneficence  
  in fetal anomaly management, 122-123  
  in maternal-fetal surgery for spina  
    bifida, 456-457  
  in nuchal translucency screening, 98-99
- Bentham, Jeremy, ethics theory of, 6
- Beta-adrenergic agonists, for preterm labor,  
  818-820
- Beta-sympathomimetic agents, for preterm  
  labor, 817-820
- Betamethasone, antenatal, for fetal maturation,  
  829-833
- Biopsy, kidney, in distal urinary tract  
  obstruction, 513
- Bipolar coagulation, of umbilical cord, in  
  multifetal pregnancies, 611-616
- Birthweight, in multifetal pregnancy, selective  
  reduction effects on, 106-107
- Bladder  
  embryology of, 508  
  obstruction of. *See* Urinary tract  
    obstruction, distal.
- Blastocyst, 29, 39
- Blastomeres, 29
- Bleeding, vaginal, preterm birth in, 657
- Blood transfusions, refusal of, in pregnancy,  
  130-131, 135
- Brain death, 36
- Braxton Hicks contractions, 809-810
- Breastfeeding, avoidance of, in HIV  
  infection, 872
- Bronchopulmonary sequestration  
  diagnosis of, 482-483  
  natural history of, 484  
  size of, 481  
  surgical treatment of, 486-487
- C**
- Calcium, in uterine activity, 806-807
- Calcium channel blockers, for preterm labor,  
  820-821, 849-850

- Capitation, in managed care, 170
- Carder, Angela, court-ordered cesarean section on, 129-134
- Care, access to, in managed care, 172-173
- Catheters  
for thoracoamniotic shunting, 485-486  
for vesicoamniotic shunting, 513-515
- Cephalocentesis, in hydrocephalus, 533
- Cerebral palsy, motor development in, 227-228
- Cervicovaginal fibronectin. *See* Fibronectin, fetal.
- Cervix  
incompetence of  
preterm labor in, 808-809  
ultrasound evaluation of, 749-752  
length of, preterm birth risk and, 654  
preparation of, for labor, 810  
ultrasound evaluation of, 735-755  
in preterm birth prediction, 738-749  
cervical incompetence in, 749-752  
in asymptomatic women, 738-741, 744-747  
in multifetal pregnancy, 746-747  
in singleton pregnancy, 744-749  
in symptomatic women, 742-743  
landmarks for, 736  
technique for, 736-738  
versus clinical examination, 736
- Cesarean delivery  
for HIV infection, 865, 868  
for nonmedical reasons, FIGO ethical guidelines for, 53-54  
managed care impact on, 176-177  
refusal of  
legal issues in, 129-133  
survey on, 134-139
- Chemical phenomenon, in gastroschisis, 553
- Chiari malformation, with myelomeningocele, 523-526
- Chorioamnionitis  
in maternal-fetal surgery, for lung lesions, 487  
neonatal outcomes in, 685  
preterm birth in, 655-656  
asymptomatic, 681  
chronicity of, 682-682  
clinical features of, 680-681  
corticosteroids for, 830  
diagnosis of, 679  
mechanisms of, 684  
organisms causing, 683-684  
origin of, 685  
premature rupture of membranes in, 691  
treatment of, 687-691  
versus gestational age, 681-682
- Chorionic villi sampling  
before multifetal pregnancy reduction, 632  
before selective reduction, 108-109  
premature membrane rupture in, amniopatch technique for, 574-580
- Chromosomal abnormalities  
in discordant twins, 603  
in gastroschisis, 552  
in multifetal pregnancies, 605-606, 631-632  
in twin reversed arterial perfusion sequence, 602  
selective termination for. *See* Selective termination.
- Chronic lung disease, prevention of, dexamethasone in, evidence-based decision-making in, 238-239
- Clewell, William, maternal-fetal surgery research by, 442-445
- Clindamycin, for intrauterine infections, 689
- Cochrane neonatal systematic reviews, 285-304, 335-336, 391-393  
results of, 287-299  
characteristics of included trials, 288-289  
distribution across subject areas, 288  
growth of output, 287-288  
observations on review methodologies, 299-300  
reviewers' conclusions, 291, 299  
size and precision of estimate of treatment effect, 290-291  
size of reviews, 290  
therapies with extensive versus limited testing, 291  
survey methods in, 286-287
- Cognitive development, follow-up data in, 228-230
- Common sense, in ethics, 9
- Communication, 17-25  
alternative word choices for, 23-24  
discriminatory, 18-19  
impact on memory, 17-18

- importance of, 17-18
  - medical language for, 19
  - obstetric language for, 20
  - of fetal anomaly test results, 115-117
  - prenatal diagnosis language for, 20-24
  - sexist, 18-19
- Confidentiality, of genetic data, 87-88
- Congenital anomalies. *See* Fetus, anomalies in.
- Congenital cystic adenomatoid malformation, of lung, 481-492
- animal studies of, 484-485
  - clinical features of, 481
  - diagnosis of, 482-483
  - natural history of, 484
  - pathology of, 482
  - size of, 482
  - surgical treatment of, 485-488
  - types of, 482
- Congenital diaphragmatic hernia, 465-479
- animal studies of, 467
  - delivery with, 473-474
  - incidence of, 465
  - mortality in, 465, 467, 475
  - natural history of, 466-467
  - prognosis for, 466-467
  - treatment of
    - postnatal, 474-475
    - prenatal, 467-473
  - ultrasonography in, 466-467
- Congenital heart disease, 541-550
- diagnosis of, 542-543
  - etiology of, 543
  - in gastroschisis, 554-555
  - treatment of
    - anesthesia in, 547
    - aortic stenosis, 544-545
    - intact atrial septum, 545-546
    - mitral stenosis, 545
    - rationale for, 543-544
    - right-sided defects, 546
    - techniques for, 547-548
- Consequentialism, 6
- Constrictive phenomenon, in gastroschisis, 552-553
- Contractions, uterine. *See* Uterus, contractions of; Home uterine activity monitoring.
- Corpus luteum, ultrasonography of, 39
- Corticosteroids, antenatal, for fetal maturation, 827-842
- American College of Obstetricians and Gynecologists opinion on, 837
  - drug selection for, 830-833
  - effects of, 827-828
  - evidence-based decision-making in, 409-412
  - in preterm premature rupture of membranes, 828-830
  - National Institutes of Health recommendations on, 836-837
  - single versus multiple courses of, 833-835
- Council of Europe, ethics code of, 51
- Counseling
  - on fetal anomalies
    - postviability, 122-124
    - previability, 118-119
  - on selective termination, in multifetal pregnancies, 604-606
- Cryoprecipitate, in amniopatch, for premature membrane rupture, 574-580, 586-587
- Culture, of amniotic fluid, 683-684
- Cystic adenomatoid malformation volume ratio, 484
- Cystoscopy, for distal urinary tract obstruction, 515-516
- Cytogenetic analysis, in multifetal pregnancies, 605
- Cytokines
  - in chorioamnionitis, 679, 684
  - in gastroschisis, 557-558
  - in preterm birth, 655-657
- Cytomegalovirus infections, preterm birth in, 694
- 
- D**
- daVinci system, for maternal-fetal surgery, 528
- De Lia, Julian, maternal-fetal surgery research by, 445-446
- Death
  - fetal, in maternal infections, 692-694
  - maternal, pregnancy management guidelines for, 53
- Decision-making
  - evidence-based. *See* Evidence-based decision-making.
  - in genetic counseling, 84-86
  - in preimplantation diagnosis, of Down syndrome, 74-75
  - on abortion
    - for anomalies, 113-114, 118-119, 122-124
    - for trisomy 13, 121-122
    - for trisomy 18, 121-122
- Declaration of Helsinki, 60-63

- Delavirdine, for HIV infection, in pregnancy, labor and delivery, 862
- Delivery, managed care impact on, 175-177
- Denver shunt, in hydrocephalus, 534-535
- Deontology, 6
- Department of Health and Human Services, maternal-fetal surgery research guidelines of, 146-152
- Dexamethasone  
antenatal, for fetal maturation, 829-833  
to prevent chronic lung disease,  
evidence-based decision-making in,  
238-239
- Diagnostic tests, **189-204**  
benefit of, to patient, 201-202  
posttest probability of disease and, 201  
pretest probability of disease and, 201  
reproducibility of, 201  
research literature on, 197-202  
case scenario in, 197, 202  
search of, for best available study,  
197-198  
study appropriateness in, 199-200  
study validity in, 198-199  
screening, 196-197  
sensitivity, specificity, and likelihood  
ratio in, 190-191, 200
- Diaphragmatic hernia. *See* Congenital diaphragmatic hernia.
- Diazoxide, for preterm labor, 822
- Didanosine, for HIV infection, in pregnancy, labor and delivery, 859-860, 862
- Diltiazem, for preterm labor, 849-850
- Disability  
prevention of, with preimplantation  
genetic diagnosis, controversy over,  
72-75  
threat of, maternal-fetal surgery for  
spina bifida and, 459-460
- Doppler studies, in congenital heart disease,  
542-543, 545
- Down syndrome  
nuchal translucency screening for,  
**95-102**  
reliability of, 95-98  
respect for autonomy in, 100  
risks versus benefits of, 98-99  
preimplantation diagnosis of,  
decision-making in, 74-75  
prenatal detection of, failure to inform  
about, 114

- Drainage  
in thoracoamniotic shunting, 485-486  
in vesicoamniotic shunting, 513-515  
of sacrococcygeal teratoma,  
497-498, 501
- Dystocia, with large sacrococcygeal  
teratoma, 494

## E

- Economic issues  
in managed care, 169-171  
in multifetal pregnancies, 624-625  
in preterm birth, 666, 757-758  
home uterine activity monitoring  
impact on, 783-784, 787
- Education, in ethics, **1-15**  
core generic course in, 11-13  
for perinatal medicine, 13  
impact of, 13-14  
introduction to, 10-11  
phases of, 10-13  
principles of  
definitions of, 1-2  
medical ethics versus general  
ethics, 2-3  
moral certainty, 6-8  
reasoning, 3-5  
trust, 8-9  
process of, 9-10  
purpose of, 9-10  
theories for, 6-8
- Efavirenz, for HIV infection, in pregnancy,  
labor and delivery, 863
- Electrical properties, of myometrium,  
667-669
- Electromyography, uterine, 670-674
- Embolization, of umbilical vessels, in selective  
termination, in multifetal pregnancies,  
606-608
- Embryo(s)  
as beginning of human life, 32-33  
definition of, 36  
extracorporeal, moral status of, 70-71  
research on, ethical issues in, 36-37  
transfer techniques for, preterm birth risk  
in, 659  
ultrasonography of, 40-42
- Embryo-chorionic circulation, ultrasonography  
of, 40
- Embryogenesis, 29-30
- Emotional development, follow-up data in, 230
- Emotional support, for fetal anomaly detection  
and management, 115

- Emtricitabine, for HIV infection, in pregnancy, labor and delivery, 862
- Endometrium, microorganism colonization of, preterm birth in, 656
- Endoscopy, for premature ruptured membrane assessment, 580-584
- Enfuvirtide, for HIV infection, in pregnancy, labor and delivery, 863
- Enzyme-linked immunosorbent assay  
for fetal fibronectin, 704  
for salivary estriol, 721
- Equipose criterion, in maternal-fetal surgery for myelomeningocele, 162-163
- Erythromycin, for intrauterine infections, 687-691
- Estriol, salivary, as preterm birth predictor, 720-727  
background of, 720-723  
confounding factors in, 721-723  
in asymptomatic women, 723-724  
in multifetal pregnancy, 726  
in symptomatic women, 724-726  
intervention studies of, 726-727
- Ethanol, for preterm labor, 815-816
- Ethics  
codes of, 45-65  
Council of Europe, 51  
FIGO (International Federation of Gynecology and Obstetrics) Committee, for Study of Ethical Aspects of Human Reproduction, 51-58  
for cesarean delivery for nonmedical reasons, 53-54  
for induced abortion for nonmedical reasons, 57-59  
for management of newborns at threshold of viability, 54-56  
for management of severely malformed newborns, 56-57  
for pregnancy management in sudden maternal death, 53  
for prenatal diagnosis, 52-53  
for research on human subjects, 59-63  
from hospital ethics committees, 46-48  
from international ethics committees, 49-58  
from national ethics committees, 48-49  
new technology impact on, 45-46  
patient-physician relationship and, 46  
United Nations Educational, Scientific, and Cultural Organization, 50  
World Health Organization, 50-51  
communication and, 17-25  
definition of, 45  
education in, 1-15  
evidence-based. *See*  
Evidence-based ethics,  
of beginning of human life, 27-44  
of fetal anomaly screening, 113-126  
of genetic counseling, 81-93  
of managed care, 167-180  
of maternal-fetal surgery  
for congenital heart defects, 543  
for multifetal pregnancy reduction, 623-624  
for myelomeningocele, 155-165  
for spina bifida, 449-464  
autonomy in, 453-455  
beneficence in, 456-457  
clinical emphasis in, 451  
controversy over, 449-450  
elective interventions in, 458-459  
moral ideas on, 451-453, 457-458  
potential abuse of, 461-462  
predisposition to treatment in, 460-461  
religious context of, 452-453  
risk considerations in, 457-458  
threat of disability in, 459-460  
uncertainty in, 455-456  
vulnerability in, 454-455  
in research programs, 141-153  
of nuchal translucency screening, 95-102  
of preimplantation diagnosis. *See* Preimplantation genetic diagnosis.  
of refusal of treatment, 127-140  
of selective reduction, 103-111
- Ethnic factors, in preterm birth, 651, 656-657
- Eugenics, 86-87
- Evidence-based decision-making. *See also* Therapeutic evidence; Treatment decisions.  
follow-up data in, 217-250  
choice of outcomes to study, 218-224  
examples of, 238-240  
group difference in, 233, 237-238  
health-related quality of life, 224  
neonatal outcome as predictor of, 225  
neurodevelopment after age 2, 229-232

- academic performance, 231-232
  - cognitive development, 229-230
  - motor development, 229
  - social and emotional development, 230
  - neurodevelopment at 1 to 2 years of age, 226-228
    - cognitive development, 228
    - hearing assessment, 226-227
    - motor development, 227-228
    - vision assessment, 227
  - no group difference in, 232-233
  - in neonatal intensive care unit. *See* Neonatal intensive care unit.
  - promoting uptake and use of, 389-402, 403-417
    - analysis of uptake process, 404-405
    - clinician awareness of proven therapies, 391-393, 405-406
    - clinician belief in evidence, 406
    - clinician commitment to change, 407
    - definition of effectiveness, 389-391
    - dissemination of new information, 393-397
      - clinician factors in, 396-397
      - comparison of methods for, 394-396
    - evaluation of new therapies, 390-391
    - evidence to support particular strategy, 405
    - examples of, 409-415
      - antenatal steroids for fetal maturation, 409-412
      - National Partnership to Help Pregnant Smokers Quit, 412-414
      - smoking cessation in routine care, 414-415
    - implementation, monitoring, and maintenance of change, 408
    - inappropriate underuse of proven therapies, 397-399
    - peer endorsement of evidence, 406-407
    - perception of gap between practice and evidence, 407
    - support for change by practice setting, 407-408
    - synergistic effects of interventions, 408-409
  - teaching of, 419-433
    - apply information to problem and evaluate outcome, 429-430
    - critically appraise evidence, 428-429
    - curriculum evaluation in, 430-431
    - obtain information with maximum efficiency, 426-428
    - recognize need for information and put in form of answerable question, 425-426
    - strategies for, 421-423
      - to faculty, 425
      - to medical students, 423-424
      - to residents and fellows, 424-425
  - Evidence-based ethics, for extremely premature infants, 363-387
    - based on credible evidence, 366
    - boundaries for care categories in, 379-381
    - chance of survival and, 366
    - cost-effectiveness in, 373-375
    - definition of, 364
    - effects on families in, 377-378, 382
    - futility of care, 364-366
    - need for improved studies of, 381
    - outcome measurements in, 368-369
    - patient factors in, 369-373
    - preventing quandaries in, 382-383
    - roles of parents and physicians in, 378-379
    - treatment withdrawal in, 377
    - types of therapeutic studies in, 367
    - use of resources and distress to infants versus benefits, 375-376
  - Ex utero intrapartum treatment (EXIT), in congenital diaphragmatic hernia, 473-474
  - Experimental therapy, in managed care, 173
  - Extracorporeal membrane oxygenation, for congenital diaphragmatic hernia, 474-475
- ## F
- Fee for service, negotiated, in managed care, 170-171
  - Feminist ethics, 7
  - Ferritin, in gastroschisis, 558
  - Fertilization
    - in vitro, multifetal pregnancy in, selective reduction in, 103-111
    - life beginning at
      - arguments against, 32-33
      - arguments for, 31-32
  - Fetoscope
    - iatrogenic membrane rupture from, amniopatch technique for, 574-580
    - invention of, 440-441

## Fetus

- anomalies in, **113-126**
  - communication about.  
*See* Communication.
  - lethal, hospice care in, 123-124
  - management of
    - aggressive, 117, 122-124
    - balancing approach to, 117, 123
    - nonaggressive, 117, 122-124
    - options for, 117
- postviability counseling and decision-making on, 122-124
- preimplantation detection of.  
*See* Preimplantation genetic diagnosis.
- previability counseling and decision-making on, 118-119
- screening and detection of
  - emotional support in, 115
  - ethical basis of, 113-114
  - giving bad news after, 115-117
  - selective reduction for, 108-109
  - viability definition and, 119-122
- fibronectin related to. *See* Fibronectin, fetal.
- genetic counseling related to. *See* Genetic counseling.
- maturation of, antenatal steroid therapy in. *See* Corticosteroids, antenatal, for fetal maturation.
- personhood of, 31, 156-160, 449-452
- research on, ethics guidelines for, 62-63
- surgery on. *See* Maternal-fetal surgery.
- ultrasonography of, 3D and 4D, 41-42
- viability of. *See* Viability, of fetus or newborn.

Fibrin formation, in amniopatch technique, 578

Fib, in glue, for premature rupture of membranes, 585-586

## Fibronectin, fetal

- as preterm birth predictor, 702-720
  - assays for, 704-705
  - confounding factors in, 705
  - historical background of, 702-705
  - in asymptomatic women, 706-709
  - in multifetal gestations, 714-717
  - in symptomatic women, 710-714
  - intervention studies of, 717-720
- in normal pregnancies, 702-704

FIGO (International Federation of Gynecology and Obstetrics) Committee, for Study of Ethical Aspects of Human Reproduction, 51-58

Financial considerations, in genetic counseling, 92

Fluid therapy, for preterm labor, 814

Formulary, limited, in managed care, 173

---

**G**

Gamete intra-fallopian transfer, preterm birth risk in, 659

Gastroesophageal reflux, treatment decisions in. *See* Treatment decisions.

**Gastroschisis, 551-572**

- amnioexchange and amniocentesis procedures for, 561-564
- amniotic fluid impact on, 559-562
- animal models of, 557-559
- consequences of, 552-553
- delivery in, 554
- diagnosis of, 553
- etiology of, 552
- genetic factors in, 552
- historical review of, 551
- incidence of, 551
- inflammation in, 557-559, 562-564
- monitoring of, 553-554
- outcome of, 555
- postnatal care in, 554-555
- prognosis for, 555-557
- surgical treatment of, 554-555

## Gender

- medical language insensitive to, 19
- prebirth selection for, 75-77, 89
- sexist language and, 18-19

Gene therapy, preimplantation genetic diagnosis and, 92

**Genetic counseling, 81-93**

- counselor responsibilities in, 84-86
- decision rights in, 84-86
  - directive, 82
  - discrimination resulting from, 88-89
  - history of, 81-82
  - illness versus health considerations in, 89-90
- means of, 82-84
  - nondirective, 82, 84-86
  - on financial costs, 92
  - on monogenic diseases, 86-87
  - on pregnancy termination, 90-91
  - on preimplantation diagnosis, 92
  - on presymptomatic diagnostics, confidentiality of data and, 87-88
  - on sex selection and determination, 89
  - religious considerations in, 91-92
  - stigmatization resulting from, 88-89

## Gestational age

- at delivery, tocolysis effects on, 852
- versus intrauterine infections, 681-682



**H**

- Harrison, Michael, maternal-fetal surgery research by, 441-442
- Health, versus illness, genetic counseling and, 89-90
- Health maintenance organizations. *See* Managed care.
- Hearing assessment, follow-up data in, 226-227
- Heart disease, congenital. *See* Congenital heart disease.
- Hernia, diaphragmatic. *See* Congenital diaphragmatic hernia.
- Highly active antiretroviral therapy, for HIV infection, in pregnancy, labor and delivery, 861
- HIV infection. *See* Human immunodeficiency virus infection.
- Home uterine activity monitoring, **757-804**  
 after tocolysis, 787-791  
 clinical trials overview of, 759  
 comprehensive system versus self-palpation, 767-768  
 controversy over, 759-760  
 devices for, 765-766  
 during maintenance tocolytic therapy, 793-797  
 economic impact of, 783-784, 787  
 false versus true, 766  
 frequency of, 764-765  
 in multifetal pregnancy, 765, 781-782  
 in secondary prevention clinical trials, 768-787  
 in socioeconomically disadvantaged group, 783-784  
 in tertiary prevention clinical trials, 787-791  
 indications for, 757-759  
 miscellaneous studies on, 791-792  
 preterm contractions, 764-765  
 preterm labor symptoms and, 766-767  
 protocol for, 761-764  
 recording strips produced in, 761-762
- Hospice care, in lethal fetal anomalies, 123-124
- Hospital ethics committees, 46-48
- Human Genome Project, genetic counseling and, 86-87
- Human immunodeficiency virus infection, preterm labor in, **857-876**  
 antenatal care in, 871  
 clinical situations in, 869-870  
 delivery mode in, 865  
 follow-up care in, 871  
 general laboratory testing in, 859-860  
 HIV testing in, 858-859  
 neonatal care in, 871-872  
 obstetric procedures in, 868-869  
 postpartum care in, 871  
 viral transmission prevention in, 860-868
- Hydrocephalus, 443-445, **531-539**  
 anomalies associated with, 531-533  
 classification of, 531-532  
 diagnosis of, 532-533  
 etiology of, 531-532  
 morbidity and mortality in, 532, 534-535  
 myelomeningocele with, 523, 525-526  
 prevalence of, 531  
 treatment of, 533-538
- Hydronephrosis, in distal urinary tract obstruction, 510
- Hydrops  
 in lung lesions, 481-486  
 in sacroccygeal teratoma, 495-503
- Hydronephrosis, in distal urinary tract obstruction, 510
- 17- $\alpha$ -Hydroxyprogesterone, for preterm labor, 822
- Hyperglycemia, from ritodrine, 819-820
- Hypnotics, for preterm labor, 821-822
- Hypoplastic left heart syndrome  
 in aortic stenosis, 544-545  
 in intact atrial septum, 545-546  
 in mitral stenosis, 545
- Hypoplastic right heart syndrome, 543, 546
- Hypotension, in premature infants, inotropes for, treatment decisions in. *See* Treatment decisions.

**I**

- Illness, versus health, genetic counseling and, 89-90
- Implantation, as beginning of human life, 33
- In vitro fertilization  
 multifetal pregnancy in, selective reduction in, 103-111  
 preterm birth risk in, 659
- Incompetence, cervical, ultrasound evaluation of, 749-752
- Indinavir, for HIV infection, in pregnancy, labor and delivery, 863

## Indomethacin

- for preterm labor, 816-817, 847, 849
- prophylactic, in low birth weight infants, evidence-based decision-making in, 239-240

## Infections

- neonatal effects of, 687
- preterm birth in, 655-656, 677-700, 809
  - ascent of, 686
  - asymptomatic, 681
  - bacterial vaginosis, 686-687
  - chronicity of, 682-683
  - diagnosis of, 679-680
  - fetal death in, 694
  - fetal fibronectin in, 704, 717-720
  - historical review of, 677-679
  - markers of, 680
  - mechanisms of, 684
  - organisms causing, 683-684
  - origin of, 685
  - premature rupture of membranes in, 691
  - sexually transmitted, 691, 693-694
  - treatment of, 687-691
  - types of, 680-681
  - versus gestational age, 681-682
  - viral, 694

## Infertility, treatments for

- multifetal pregnancy in, 103-105
- religious teachings on, 34

## Inflammation, in gastroschisis, 557-559, 562-564

## Informed choice, in maternal-fetal surgery for spina bifida, 460-461

## Informed consent

- for nuchal translucency screening, 100
- for preimplantation genetic diagnosis, 69

Inotropes, for hypotension, in premature infants, treatment decisions in. *See* Treatment decisions.Intensive care unit, neonatal. *See under* Neonatal intensive care unit.

## Interleukin(s), in gastroschisis, 557-558, 562-563

## International ethics committees

- codes of, 49-58
- Council of Europe, 51
- United Nations Educational, Scientific, and Cultural Organization, 50
- World Health Organization, 50-51

## International Federation of Gynecology and Obstetrics (FIGO) Committee, for Study of Ethical Aspects of Human Reproduction, 51-58

## International Fetal Medicine and Surgery Society, 444

## International Fetoscopy Group, 440-441

## Intestine

- exteriorization of, in gastroschisis, 552
- pathology of, in gastroschisis, 553-554

## Intrauterine growth retardation

- after multifetal pregnancy reduction, 631
- in gastroschisis, 554, 563

## Intrauterine pressure catheters, for preterm labor detection, 667

## Isoxuprine, for preterm labor, 818

---

**J**

## Justice principle, preimplantation genetic diagnosis and, 69

---

**K**

## Kant, Immanuel, ethics theory of, 6

## Karyotyping, for genetic diagnosis in selective reduction, 108-109

## Keratinocyte growth factor, in congenital cystic adenomatoid malformation, 482

## Kidney

- biopsy of, in distal urinary tract obstruction, 513
- damage of, in urethral obstruction, 507-510

---

**L**Labor and delivery. *See also* Cesarean delivery. diagnosis of

- clinical, 666-667
- electromyography in, 670-674
- in congenital diaphragmatic hernia, 473-474
- in gastroschisis, 555
- in HIV infection, 865, 868
- in hydrocephalus, 533-534
- in large sacrococcygeal teratoma, 494
- premature. *See* Premature labor and delivery.
- preparatory stage of, 669-670

## Lamivudine, for HIV infection, in pregnancy, labor and delivery, 862, 864

Language. *See* Communication.

## Laser therapy

- for premature rupture of membranes, 584-586

- for sacrococcygeal teratoma, 500-501
  - for selective termination, in multifetal pregnancies, 607, 610
  - for twin-twin transfusion syndrome, 595-597
  - Leg function, after myelomeningocele repair, 526
  - Legal issues
    - in managed care, 174-175
    - in refusal of treatment, 128-134
    - in viability definition, 119-122
  - Length of stay, for delivery, in managed care, 175-176
  - Leukocytes, in chorioamnionitis, 679
  - Life, 27-44
    - beginning of
      - at fertilization
        - arguments against, 32-33
        - arguments for, 31-32
      - biologic view of, 28-29
      - controversies on, 35-36
      - embryo research and, 36-37
      - embryogenesis and, 29-30
      - religious teachings on, 33-35
      - visualization of, 37-42
    - definition of, 27
    - ending of, controversies on, 35-36
    - personality and, 30-31
  - Life support, withholding or withdrawal of
    - for newborns at threshold of viability, ethics of, 54-55
    - for severely malformed newborns, ethics of, 56-57
  - Lifestyle risks, for preterm birth, 659-660
  - Litigation, managed care and, 174-175
  - Liver, position of, in congenital diaphragmatic hernia, 466-467, 474
  - Lopinavir, for HIV infection, in pregnancy, labor and delivery, 863
  - Low birth weight infants
    - low bilirubin levels in, phototherapy for, treatment decisions in. *See* Treatment decisions.
    - prophylactic indomethacin in, evidence-based decision-making in, 239-240
  - Lung
    - agenesis of, 483
    - bronchopulmonary sequestration in, 481-484, 486-487
    - congenital cystic adenomatoid malformation of, 481-492
    - hypoplasia of
      - in congenital diaphragmatic hernia, 465-475
      - in oligohydramnios, 507
    - maturation of, corticosteroids for. *See* Corticosteroids, antenatal, for fetal maturation.
  - Lung-to-head-ratio, in congenital diaphragmatic hernia, 466-467
  - Lysosomes, in uterine activity, 807
- 
- M**
- Magnesium preparations, for preterm labor, 814-815, 848
  - Magnetic resonance imaging, in hydrocephalus, 533
  - Magnetic resonance spectroscopy, in urine analysis, in distal urinary tract obstruction, 513
  - Managed care, 167-180
    - ethical issues in
      - access to care, 172-173
      - cesarean section, 176-177
      - costs, 169-170
      - experimental therapy, 173
      - length of stay, 175-176
      - level III neonatal care, 178
      - limited formulary, 173
      - litigation, 174-175
      - patient education, 172
      - patient-physician relationship, 168-169
      - payment methodologies, 170-171
      - physician selection, 171
      - pre-certification, 172-173
      - preventive services, 172
      - quality management, 171-172
      - range of benefits, 172
      - referral to maternal fetal medicine specialists, 178-179
      - role of, 173-174
      - standards of practice, 171
      - ultrasound use, 177-178
    - history of, 167-168
  - Marketing, of preimplantation genetic diagnosis, 68-69
  - Maternal-fetal medicine specialists, referral to, in managed care, 178-179
  - Maternal-fetal surgery
    - coercion in, 157
    - ethics of
      - in congenital heart disease, 543
      - in multifetal pregnancy reduction, 623-624

- in spina bifida, **449-464**, 543, 623-624
  - for anomalies, counseling on, 118-119, 122-124
  - for complicated multifetal pregnancy management, **601-621**
  - for congenital heart disease, **541-550**
  - for diaphragmatic hernia, **465-479**
  - for distal urinary obstruction, **507-519**
  - for gastroschisis, **551-572**
  - for hydrocephalus, 443-445, **531-539**
  - for lung lesions, **481-492**
  - for multifetal pregnancy reduction, **623-641**
  - for myelomeningocele, **155-165**, **521-530**, 533
    - equipoise criterion in, 162-163
    - outcome of, 160-161
    - patient definition in, 156-160
    - research on, 160-163
    - risks of, 161-162
  - for premature ruptured membrane repair, **573-589**
  - for sacrococcygeal teratoma, **493-506**
  - for selective termination. *See* Selective termination.
  - for twin-twin transfusion syndrome. *See* Twin-twin transfusion syndrome.
  - history of, **439-447**
  - research on, **141-153**
    - current status of, 141-144
    - ethical concerns in, 145-146
    - federal rules on, 146-152
    - technical details of, 144-145
  - risks of, 144-145
- Maternal mirror syndrome
- fetal lung lesions and, 487-488
  - sacrococcygeal teratoma and, 496-497
- Matrix metalloproteinases, in chorioamnionitis, 679, 684
- Mechanical ventilation, for congenital diaphragmatic hernia, 474-475
- Membrane rupture
- iatrogenic, between twins, for twin-twin transfusion syndrome, 596
  - premature. *See* Premature ruptured membranes.
- Mesenteric vascularization, in gastroschisis, 554
- Methylxanthines, for neonatal apnea, treatment decisions in. *See* Treatment decisions.
- Metronidazole, for intrauterine infections, 688-690, 718
- Mezlocillin, for intrauterine infections, 687
- $\beta$ 2-Microglobulin measurement, in distal urinary tract obstruction, 512
- Mill, John Stuart, ethics theory of, 6
- Mirror syndrome
- fetal lung lesions and, 487-488
  - sacrococcygeal teratoma and, 496-497
- Mitral stenosis, treatment of, 545
- Monitoring, of uterine contractions, at home. *See* Home uterine activity monitoring.
- Monopolar coagulation, of umbilical cord, in multifetal pregnancies, 610-611
- Moral certainty, 6-8
- Moral issues, in maternal-fetal surgery for spina bifida
- personhood, 451-452
  - religious context of, 452-453
  - risks, 457-458
- Morality, versus ethics, 1-2
- Motor development, follow-up data in, 227-229
- Multifetal pregnancy, **623-641**. *See also* Twin-twin transfusion syndrome.
- causes of, 103-104
  - complications of, 624-625
  - costs of, 624-625
  - home uterine activity monitoring impact on, 765, 781-782
  - incidence of, 623
  - natural history of, 624-625
  - nuchal translucency screening in, 99
  - preterm birth in, 624, 658-659, 758
    - cervical ultrasound evaluation in, 746-747
    - fetal fibronectin in, 714-717
    - salivary estriol measurement in, 726
  - public fascination with, 104-105
  - reduction of
    - cervical length after, 634
    - chromosomal abnormalities and, 631-632
    - controversies in, 634-635, 638
    - ethics of, 633-634
    - follow-up after, 632-633
    - gestational age at delivery and, 628
    - historical aspects of, 625
    - intrauterine growth retardation and, 631
    - outcome of, 630-631, 636-637
    - pregnancy loss in, 626-630, 635-636
    - presenting fetus and, 635
    - psychological aspects of, 633
    - selective, 103-111, 635-639

- technical aspects of, 625-626,  
637-638  
to singleton, 634  
transvaginal, 630  
vascular occlusion techniques for,  
601-621  
    genetic counseling in,  
    604-606  
    in discordant twin  
    anomalies, 603  
    in twin-twin transfusion syn-  
    drome, 596, 603-616  
    in twin reversed arterial  
    perfusion sequence,  
    602-603  
    indications for, 602-604  
    methods for, 606-616  
    psychosocial aspects of, 616  
risks in, 103  
statistics on, 103
- Myelomeningocele  
    hydrocephalus with, 533  
    maternal-fetal surgery for, 155-165,  
    521-530  
    developmental aspects and,  
    522-524  
    equipoise criterion in, 162-163  
    ethics of. *See* Ethics, of maternal-  
    fetal surgery, for spina bifida.  
    future research on, 528  
    historical review of, 524-525  
    outcome of, 160-161  
    patient definition in, 156-160  
    randomized, controlled clinical  
    trials of, 521-522, 527  
    research on, 160-163  
    results of  
        Chiari malformation, 526  
        hydrocephalus, 525-526  
        leg function, 526  
        morbidity and mortality,  
        526-527  
    risks of, 161-162
- Myometrium  
    electrical properties of, 667-669  
    physiology of, 806-807
- N**
- Narcotics, for preterm labor, 821-822
- Narrative ethics, 7
- National Commission for the Protection of  
    Human Subjects of Biomedical and  
    Behavioral Research, 49, 62-63
- National ethics committees, 48-49
- National Human Research Protections  
    Advisory Committee, on maternal-fetal  
    surgery research, 147-150
- National Partnership to Help Smokers Quit,  
    evidence-based decision-making in,  
    412-414
- Nelfinavir, for HIV infection, in pregnancy,  
    labor and delivery, 863
- Neonatal intensive care unit  
    evidence-based decision-making in,  
    333-342  
        clinical research and, 336-337  
        evaluation of practice in, 340  
        ingredients of, 334-335  
        systematic reviews in, 335-336  
        using summarized evidence to  
        inform clinical practice,  
        338-339  
    validity of protocols in, 339-340  
    level III, in managed care, 178
- Neural tube defects. *See*  
    also Myelomeningocele.  
    in multifetal pregnancies, 605
- Neurodevelopmental outcome, follow-up data  
    in. *See* Evidence-based decision-making.
- Nevirapine, for HIV infection, in pregnancy,  
    labor and delivery, 862, 864-867
- Newborns  
    at threshold of viability, FIGO ethical  
    guidelines for, 54-56  
    severely malformed, FIGO ethical  
    guidelines for, 56-57  
    viability of. *See* Viability, of fetus  
    or newborn.
- Nicardipine, for preterm labor, 821
- Nifedipine, for preterm labor, 821, 849-850
- Nitric oxide, for congenital diaphragmatic  
    hernia, 475
- Nomenclature. *See* Communication.
- Nuchal translucency screening, 95-102  
    reliability of, 95-98  
    respect for autonomy in, 100  
    risks versus benefits of, 98-99
- Nuremberg Code, 59-60
- O**
- Obstructive uropathy. *See* Urinary tract  
    obstruction, distal.
- Octuplets. *See* Multifetal pregnancy.
- Oligohydramnios  
    in fetal distal urinary obstruction,  
    507-511, 515

- in gastroschisis, 553-554, 561-564  
in twin-twin transfusion syndrome, 591, 593  
isolated, versus twin-twin transfusion syndrome, 593
- Oncofetal fibronectin. *See* Fibronectin, fetal.
- Oocytes, ultrasonography of, 39
- Opioids, for preterm labor, 821-822
- Ovulation induction, preterm birth risk in, 659
- Oxygen therapy  
for respiratory distress syndrome, treatment decisions in, 337  
in delivery room, treatment decisions in. *See* Treatment decisions.
- Oxytocin, in uterine activity, 806-807
- Oxytocin receptor antagonists, for preterm labor, 849
- P**
- Palpation, of uterine contractions, versus tocodynamometer system, 767-768
- Partial liquid ventilation, for congenital diaphragmatic hernia, 474-475
- Patient-physician relationship  
in ethics codes, 46  
in managed care, 168-169
- Payment, of physicians, in managed care, 170-171
- Percival, Thomas, ethics code of, 5
- Periodontal infections, preterm birth in, 693-694
- Peritonitis, in gastroschisis, 552
- Perivisceritis, in gastroschisis, 553-554, 556-558, 560-561
- Personality, definition of, 30-31
- Phosphodiesterase inhibitors, for preterm labor, 821
- Phospholipase A<sub>2</sub>, in uterine activity, 807
- Phototherapy, for low bilirubin levels, in low birth weight infants, treatment decisions in. *See* Treatment decisions.
- Placenta  
anastomoses of, in twin-twin transfusion syndrome, 592-593  
circulation of, ultrasonography of, 40-41
- Placentomegaly, in sacrococcygeal teratoma, 495-498
- Platelet(s), in amniopatch, for premature membrane rupture, 574-580, 586-587
- Platelet-derived growth factor, in congenital cystic adenomatoid malformation, 482
- Plug the lung strategy, for congenital diaphragmatic hernia, 468
- Polyhydramnios  
in twin-twin transfusion syndrome, 591, 593  
isolated, versus twin-twin transfusion syndrome, 593
- Posterior urethral valves  
evaluation of, 512-513  
treatment of, 513-516
- Potassium chloride, for multifetal pregnancy reduction controversies in, 634-635  
ethics of, 633-634  
follow-up after, 632-633  
from three to two, 630-631  
genetic testing before, 631-632  
gestational age at delivery and, 628  
intrauterine growth retardation from, 631  
pregnancy loss in, 626-630  
psychological aspects of, 633  
selective termination in, 635-639  
technique for, 625-626  
transvaginal, 630
- Pre-certification, in managed care, 172-173
- Pre-embryo, description of, 29-30
- Predisposition to treatment, in maternal-fetal surgery for spina bifida, 460-461
- Pregnancy. *See also* Uterus.  
bleeding in, preterm birth in, 657  
cervical length in, preterm birth and, 654  
cervical ultrasound evaluation in, 735-755  
drug abuse in, criminalization of, 157-158  
fetal surgery during. *See* Maternal-fetal surgery.  
genetic counseling related to. *See* Genetic counseling.  
infections in, preterm birth and, 655-656  
multifetal. *See* Multifetal pregnancy.  
nuchal translucency screening in, 95-102  
refusal of treatment during, 127-140  
legal issues in, 128-134  
survey of maternal-fetal fellowship directors on, 134-139  
sudden maternal death in, FIGO ethical guidelines for, 53  
tentative, prenatal diagnosis and, 22  
termination of. *See* Abortion.

- Preimplantation genetic diagnosis, 67-80  
 clinician's conscience and, 78-79  
 description of, 67  
 embryogenesis stages and, 29-30  
 ethical issues in  
 disclosure, 69  
 in offering procedure, 68-70  
 informed consent, 69  
 moral status of extracorporeal embryo, 70-71  
 reimbursement, 68-69  
 socioeconomic status and, 69  
 for desirable characteristics selection, 75-77  
 for sex selection, 75-77  
 gene therapy and, 92  
 marketing of, 68-69  
 of serious diseases and disabilities, 72-75  
 purpose of, 71-72  
 statistics on, 67
- Premature infants, selective reduction and, 106-107
- Premature labor and delivery  
 definition of, 665-666, 809-811  
 diagnosis of, 810-812  
 economic costs of, 666, 757-758  
 epidemiology of, 651-664, 677, 757  
 history of, 653-654  
 home uterine activity monitoring for, 757-804  
 in discordant twins, 603  
 in HIV infection, 859-878  
 in maternal-fetal surgery, for myelomeningocele, 527  
 in multifetal pregnancies, 624, 628, 637  
 in twin reversed arterial perfusion sequence, 602  
 indicated versus spontaneous, 652  
 infections causing. *See* Infections, preterm birth in.  
 management of, 805-826. *See also* Tocolysis.  
 bedrest in, 813-814  
 beta-sympathomimetic agents in, 817-820  
 calcium channel blockers in, 820-821  
 decisions in, 811-812  
 ethanol in, 815-816  
 fluid therapy in, 814  
 future considerations in, 822-823  
 goals of, 812-813  
 magnesium sulfate in, 814-815  
 phosphodiesterase inhibitors in, 821  
 prostaglandin synthase inhibitors in, 816-817  
 patterns of, 653
- prediction of  
 biochemical, 701-733  
 cervical ultrasound in, 735-755  
 predisposing factors in, 808-809  
 prevention of  
 corticosteroids for, 827-842  
 tocolysis in, 843-855  
 recurrent, 653-654, 851  
 risk factors for, 651-660  
 spontaneous versus indicated, 652  
 symptoms of, 766-767  
 uterine contraction physiology in, 665-676, 806-807
- Premature ruptured membranes  
 preterm, corticosteroids use in, 828-830  
 treatment of, 573-589, 691  
 animal models of, 585-586  
 iatrogenic, amniopatch for, 574-580  
 spontaneous, 580-587  
 amniopatch for, 586-587  
 endoscopic assessment for, 580-584  
 surgical, 584-587
- Prenatal diagnosis. *See also* Fetus, anomalies of, screening and detection of;  
 Preimplantation genetic diagnosis, communication about.  
*See* Communication.  
 FIGO ethical guidelines for, 52-53  
 genetic counseling with, 82-84  
 language used in, 20-24
- Prenatal surgery. *See* Maternal-fetal surgery.
- Presymptomatic diagnosis, ethical issues in, 87-88
- Preterm birth. *See* Premature labor and delivery.
- Preventive health services, in managed care, 172
- Principalism, 6-7
- Progesterone, for preterm labor, 822
- Prostaglandin(s)  
 fetal need for, 817  
 in uterine activity, 806-807, 809
- Prostaglandin synthetase inhibitors, for preterm labor, 816-817, 848-849
- Psychosocial issues  
 in multifetal pregnancy reduction, 623  
 in selective termination, 616
- Pulmonary arteries, hypoplastic, treatment of, 546
- Pulmonary atresia, with intact ventricular septum, treatment of, 546

**Q**

Quadruplets. *See* Multifetal pregnancy.

Quality management, in managed care, 171-172

Quintuplets. *See* Multifetal pregnancy.

**R**

Racial factors, in preterm birth, 651, 656-657

Radiofrequency ablation, of sacrococcygeal teratoma, 501-503

Reasoning, ethical, 3-5

Reduction, selective. *See* Selective termination.

Reimbursement, for preimplantation genetic diagnosis, 68-69

Religious context, of maternal-fetal surgery for spina bifida, 452-453

Religious teachings  
genetic counseling and, 91-92  
on beginning of life, 33-35

Research

- on fetuses, ethics guidelines for, 62-63
- on human subjects, international ethics codes for, 59-63
- on maternal-fetal surgery. *See* Maternal-fetal surgery.

Respiratory distress syndrome

- oxygen therapy for, treatment decisions in, 337
- surfactant therapy for, treatment decisions in, 336-337

Ritodrine, for preterm labor, 819-820, 846

Ritonavir, for HIV infection, in pregnancy, labor and delivery, 863

Rodeck, Charles, maternal-fetal surgery research by, 440-441

Ruptured membranes

- iatrogenic, between twins, for twin-twin transfusion syndrome, 596
- premature. *See* Premature ruptured membranes.

**S**

Sacrococcygeal teratoma, 493-506

- diagnosis of, 495-496
- dystocia due to, 494
- epidemiology of, 493
- grading system for, 493
- histology of, 493, 495
- malignant, 494-495
- maternal mirror syndrome and, 496-497

- natural history of, 496
- surgical treatment of, 497-504

Salivary estriol, as preterm birth predictor, 720-727

Saquinavir, for HIV infection, in pregnancy, labor and delivery, 863

Sedatives, for preterm labor, 821-822

Selective laser photocoagulation of communicating vessels, for twin-twin transfusion syndrome, 595-597

Selective termination, 103-111

- controversy over, 103
- in multifetal pregnancies
  - bipolar cord coagulation in, 611-616
  - controversies in, 638
  - counseling for, 604-606
  - embolization in, 606-608
  - fetoscopic cord ligation in, 607, 609
  - indications for, 602-604
  - laser photocoagulation of cord in, 607-608, 610
  - monopolar cord coagulation in, 610-611
  - outcomes of, 636-637
  - overlap with reduction, 638-639
  - pregnancy loss in, 635-636
  - psychosocial aspects of, 616
  - technical aspects of, 637-638
  - vascular occlusion techniques for. *See under* Multifetal pregnancy, reduction of.
- outcomes of, 105-108
- patient issues in, 108-109
- procedures for, 105

Septostomy, for twin-twin transfusion syndrome, 496

Septuplets. *See* Multifetal pregnancy.

Sex, prebirth selection for, 75-77, 89

Sextuplets. *See* Multifetal pregnancy.

Sexually transmitted infections, preterm birth in, 691-694

Shunts

- thoracoamniotic, for lung lesions, 485-486
- ventriculoamniotic, in hydrocephalus, 534-538
- vesicoamniotic, for distal urinary tract obstruction, 513-515

Smoking

- cessation of, in routine medical care, evidence-based decision-making in, 414-415
- preterm risk birth in, 659



Social development, follow-up data in, 230

Socioeconomic factors, in preterm birth, 656-657, 808

Spermatozoa, as being, controversy over, 35

#### Spina bifida

- hydrocephalus with, 533
- prenatal treatment of, **521-530**
  - clinical trials of, 527
  - developmental aspects and, 522-524
  - ethics of. *See* Ethics, of maternal-fetal surgery, for spina bifida.
  - future research on, 528
  - historical review of, 524-525
  - results of
    - Chiari malformation, 526
    - hydrocephalus, 525-526
    - leg function, 526
    - morbidity and mortality, 526-527

Standards of care, in managed care, 171

State Child Health Insurance Program, fetal coverage considerations in, 157

Stavudine, for HIV infection, in pregnancy, labor and delivery, 859-860, 862

Stem cell research, ethical issues in, 36-37

Stillbirths, in maternal infections, 692-693

Sulindac, for preterm labor, 817, 848-849

#### Surfactant

- deficiency of, in congenital diaphragmatic hernia, 471, 475
- replacement of, for respiratory distress syndrome, treatment decisions in, 336-337

Surgery, maternal-fetal. *See* Maternal-fetal surgery.

Susceptibility testing, for genetic disorders, ethical issues in, 87-88

## T

Tenofovir, for HIV infection, in pregnancy, labor and delivery, 862

Teratoma, sacrococcygeal, **493-506**

#### Terbutaline

- for preterm labor, 819-820, 846-847
- for tocolysis, home uterine activity monitoring during, 793-797

Tetralogy of Fallot, treatment of, 546

Therapeutic evidence. *See also* Evidence-based decision-making; Treatment decisions. statistics in, **205-215**

- adjusting for baseline differences, 211-212
- appropriateness of analysis, 210
- confounding variables, 211-212
- number needed to treat, 213
- observational studies, 213-214
- P* value greater than 0.05, 208-210
- P* value less than 0.05, 206-208
- randomized trials, 212-213
- rationale for, 205-206

#### Thermocoagulation

- of sacrococcygeal teratoma, 501, 503
- of umbilical cord, in
  - multifetal pregnancies
  - bipolar, in multifetal pregnancies, 611-616
  - monopolar, 610-611

Thoracoamniotic shunting, for lung lesions, 485-486

#### Tocodynamometers

- for home uterine contraction monitoring. *See* Home uterine activity monitoring.
- for preterm labor detection, 667

#### Tocolysis

- bedrest in, 813-814
- beta-adrenergic agents in, 846-848
- beta-sympathomimetic agents in, 817-820
- calcium channel blockers in, 820-821, 849-850
- decisions about, 810-812
- ethanol in, 815-816
- fluid therapy in, 814
- future considerations for, 822-823
- goals of, 812-813
- home uterine activity monitoring after, 787-791
- home uterine activity monitoring during, 793-797
- magnesium preparations in, 814-815, 848
- maintenance, **843-856**
  - beta-adrenergic agents in, 846-848
  - calcium channel blockers in, 849-850
  - literature review on, 844-846
  - magnesium in, 848
  - oxytocin receptor antagonists in, 849
  - prostaglandin synthetase inhibitors in, 848-849
  - results of, 850-855
- oxytocin receptor antagonists in, 849

- phosphodiesterase inhibitors in, 821
- prostaglandin synthetase inhibitors in, 816-817, 848-849
- Tracheal occlusion procedure, for congenital diaphragmatic hernia, 468-473
- Transfusions, refusal of, in pregnancy, 130-131, 135
- TRAP (twin reversed arterial perfusion sequence), vascular occlusion techniques for, 602-603
- Treatment
  - refusal of, during pregnancy, **127-140**
  - withholding or withdrawal of
    - for newborns at threshold of viability, ethics of, 54-55
    - for severely malformed newborns, ethics of, 56-57
- Treatment decisions, **351-361**. *See also* Evidence-based decision-making; Therapeutic evidence.
  - controlled human experiments in, historical aspects of, 354-355
  - evidence versus practice in, **305-331**
    - antibiotics in asymptomatic premature infants, 322-325
      - current practice, 324-325
      - evidence against, 323-324
      - evidence supporting, 322-323
      - future practice, 325
      - quality of evidence, 325
      - recommendations, 325
    - delivery room-assisted ventilation with 100% oxygen, 319-322
      - current practice, 321
      - evidence against, 319-321
      - evidence supporting, 319
      - future practice, 321
      - quality of evidence, 322
      - recommendations, 322
    - inotropes for hypotension in premature infants, 311-314
      - current practice, 314
      - evidence against, 312-314
      - evidence supporting, 311-312
      - future practice, 314
      - quality of evidence, 314
      - recommendations, 314
    - methylxanthines for neonatal apnea, 309-311
      - current practice, 311
      - evidence against, 310-311
      - evidence supporting, 309-310
    - future practice, 311
    - quality of evidence, 311
    - recommendations, 311
  - phototherapy in extremely low birth weight infants, 305, 307-309
    - current practice, 309
    - evidence against, 307-308
    - evidence supporting, 305, 307
    - future practice, 309
    - quality of evidence, 309
    - recommendations, 309
  - therapy for gastroesophageal reflux, 314-316
    - current practice, 318
    - evidence against, 316-318
    - evidence supporting, 314-316
    - future practice, 318
    - quality of evidence, 318-319
    - recommendations, 319
  - in public health interventions, 355-357
    - randomized trials in, 357-358
    - obstacles to, 358-359
  - observational studies and, **269-283**
    - case-control studies in, 276-277
    - cautionary notes in, 280-281
    - cohort studies in, 274-276
    - effect size in, 278
    - evidence of causal association in, 277-278
    - external validity in, 273
    - internal validity in, 272-273
    - lack of other explanations in, 279-280
    - population-wide data in, 279
    - reporting analytical studies in, 280
    - temporal proximity of treatment and outcome in, 278
    - types of research designs in, 270-271
    - value of ecologic designs in, 278-279
    - versus experimental analyses, 352-354
    - when randomized, controlled trial not possible, 273
  - risks versus benefits of, **251-268**
    - assessing values attached to outcomes, 260, 262
    - integrating values into decisions, 262-267
    - measuring effects of, 254-257
    - minimum event need to justify treatment, 257-258
    - threshold number needed to treat, 257
    - derivation of, 258-259
    - factors influencing, 259
- Triplets. *See* Multifetal pregnancy.

- Trisomy 13, abortion decision-making in, 121-122
- Trisomy 18, abortion decision-making in, 121-122
- Trisomy 21. *See* Down syndrome.
- Trust, in ethics, 8-9
- Tumor(s)  
     congenital cystic adenomatoid malformation, of lung, 481-492  
     sacroccygeal teratoma, **493-506**
- Tumor necrosis factor- $\alpha$ , in gastroschisis, 557-558, 562-563
- Twin(s). *See also* Multifetal pregnancy.  
     preterm birth risk for, 658-659  
         cervical ultrasound evaluation in, 746-747  
         fetal fibronectin measurement in, 714-717  
     triplet pregnancy reduced to, 630-631
- Twin-twin transfusion syndrome, **591-600**  
     chromosomal abnormalities in, 605-606  
     definition of, 591-592  
     diagnosis of, 593  
     differential diagnosis of, 593  
     etiology of, 592-593  
     in multifetal pregnancies, 591  
     incidence of, 592, 603  
     mortality in, 594, 597  
     pathophysiology of, 604  
     reversed arterial perfusion sequence in, 602-603  
     staging of, 593-594  
     treatment of, 594-597, 604  
         early development of, 445-446  
         laser therapy in, 595-597  
         septostomy in, 596  
         serial amniocentesis in, 594-597  
         single fetal demise in, 597  
         umbilical cord occlusion in, 596, 606-616
- Twin reversed arterial perfusion sequence, vascular occlusion techniques for, 602-603

## U

### Ultrasonography

#### fetal

- bonding during, 21
- in chromosomal abnormalities, in multifetal pregnancies, 605
- in congenital cystic adenomatoid malformation, 482-483
- in congenital diaphragmatic hernia, 466-467

- in congenital heart disease, 542-543
- in distal urinary tract obstruction, 510, 512
- in early human development, 37-42
- in gastroschisis, 553
- in genetic counseling, 82-84
- in hydrocephalus, 532-533
- in nuchal translucency screening, ethical dimensions of, 95-102
- in sacroccygeal teratoma, 495
- in selective reduction, 105
- in twin-twin transfusion syndrome, 593
- indications for, in managed care, 177-178
- insensitive terms used in, 19
- maternal, in cervical evaluation, 735-755

### Umbilical cord

- occlusion of, for twin-twin transfusion syndrome, 596
- procedures involving, in multifetal pregnancies  
         bipolar cord coagulation, 611-616  
         laser photocoagulation, 607, 610  
         ligation, 607, 609  
         monopolar coagulation, 610-611

### United Nations Educational, Scientific, and Cultural Organization (UNESCO), ethics code of, 50

### Urethra

- abnormalities of. *See* Urinary tract obstruction, distal.
- embryology of, 508

### Urinalysis, in distal urinary tract obstruction, 512-513

### Urinary tract infections, maternal, preterm birth in, 693

### Urinary tract obstruction, distal, **507-519**

- animal models of, 508-510
- diagnosis of, 510-511
- differential diagnosis of, 511
- embryologic considerations in, 508
- etiology of, 507
- morbidity and mortality from, 507
- treatment of, 511-516  
         cystoscopy in, 515-516  
         evaluation for, 511  
         in posterior urethral valves, 512-513  
         rationale for, 512-513  
         vesicoamniotic shunting in, 513-515

## Uterus

- anomalies of, preterm birth and, 657-658
- contractions of, **665-676**
  - Braxton Hicks, 809-810
  - electromyography of, 670-674
  - frequency of, preterm birth and, 658
- home monitoring of. *See* Home uterine activity monitoring
- in labor diagnosis, 666-667
- in preparatory stage, 669-670
- model for, 669-670
- myometrial physiology in, 667-674
- physiology of, 806-807
- overdistention of, preterm birth in, 809
- structural defects of, preterm labor in, 808-809

## Utilitarianism, 6

---

V

---

- Vagina, fibronectin in. *See* Fibronectin, fetal.
- Vaginal bleeding, preterm birth in, 657
- Vaginitis, bacterial, preterm birth in, 655-656, 686-687, 690-691
- Valvuloplasty, balloon, for congenital heart disease
  - evaluation for, 542-543
  - left-sided, 544-546
  - rationale for, 543-544
  - right-sided, 546
  - techniques for, 547-548
- Vascular occlusion techniques, for multifetal pregnancies. *See under* Multifetal pregnancy, reduction of.
- Ventilation, in delivery room, treatment decisions in. *See* Treatment decisions.
- Ventricular septum, intact, treatment of, 546
- Ventriculoamniotic shunt, in hydrocephalus, 534-538
- Ventriculomegaly, in hydrocephalus, 532
- Vesicoamniotic shunt, for distal urinary tract obstruction, 513-515
- Viability, of fetus or newborn
  - anencephalic, 119-121
  - at threshold, FIGO ethical guidelines for, 54-56
  - federal definition of, 147
  - legal definition of, 119-122

- patient status and, 159-160
- with anomalies
  - counseling after, 122-124
  - counseling before, 118-119

- Video-assisted fetal endoscopy, for congenital diaphragmatic hernia, 468
- Viral infections, preterm birth in, 694
- Virtue ethics, 7
- Vision assessment, follow-up data in, 227
- Visual analog scale, and treatment decisions, 260
- Vulnerability, in maternal-fetal surgery for spina bifida, 454-455

---

W

---

- Warnock Committee on Human Fertilization and Embryology, 49
- Withholding or withdrawal of care
  - for newborns at threshold of viability, ethics of, 54-55
  - for severely malformed newborns, ethics of, 56-57
- World Association of Perinatal Medicine, Ethical Committee of, 51
- World Health Organization, ethics code of, 50-51
- World Medical Association, Declaration of Helsinki, 60-63

---

Y

---

- Yolk sac, ultrasonography of, 39-40

---

Z

---

- Zalcitabine, for HIV infection, in pregnancy, labor and delivery, 862
- Zidovudine, for HIV infection
  - in neonates, 870, 872
  - in pregnancy, labor and delivery, 860-862, 864-870
- Zygote, as beginning of human life, 31-32
- Zygote intra-fallopian transfer, preterm birth risk in, 659

